Malignant Digestive System Neoplasm

124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray. The TC/CC genotype of p14ARF at rs3814960 had decreased overall survival (HR = 2.77, 95% CI: 1.3… (full text at CIViC)

PMID 27414035 · Li et al., 2016 · Open in CIViC

Patients with stage II/III colorectal cancer were analyzed for expression of CDX2 (by microarray and IHC). In the discovery (466 patients) and validation sets (314 patients), 5-year DFS was lower amon… (full text at CIViC)

PMID 26789870 · Dalerba et al., 2016 · Open in CIViC

In patients with stage II colon cancer, positive CDX2 status was associated with longer overall survival.

PMID 26789877 · Boland et al., 2016 · Open in CIViC

In a clinical study including 164 patients, CEACAM1-L dominant expression is significantly associated with decreased OS by a multivariate analysis (p = 0.02).

PMID 21413011 · Ieda et al., 2011 · Open in CIViC

In a clinical study including 128 patients, CEACAM1-L dominant expression is significantly associated with decreased recurrence-free survival rate by a multivariate analysis (p = 0.04). Moreover CEACA… (full text at CIViC)

PMID 24390710 · Kiriyama et al., 2014 · Open in CIViC

In a clinical study including 67 patients with liver metastases, enhanced CEACAM1-S expression in the state of CEACAM-L dominance at the primary tumor invasion front is significantly correlated with d… (full text at CIViC)

PMID 29180203 · Yamaguchi et al., 2017 · Open in CIViC

A 35 year-old patient presented with a grade 3 pancreatic neuroendocrine tumor and liver metastasis. Whole genome sequencing and RNAseq revealed a previously undescribed somatic translocation between … (full text at CIViC)

PMID 31160355 · Williamson et al., 2019 · Open in CIViC

CIC knockout conferred resistance to selumetinib in KRAS G12V (PATU8902) pancreatic cancer cells.

PMID 28178529 · Wang et al., 2017 · Open in CIViC

In a CRISPR-Cas9 screen in two KRAS G12V pancreatic cancer cell lines (PATU8902, PATU8988T), CIC was found to promote proliferation/survival in the context of trametinib treatment. Additional in vitro… (full text at CIViC)

PMID 28178529 · Wang et al., 2017 · Open in CIViC

Expression of the protein CIP2A was investigated in 72 cases of pancreatic ductal adenocarcinoma and 27 cases of adjacent tissues. Immunohistochemistry revealed a significant difference in expression … (full text at CIViC)

PMID 26894380 · Xu et al., 2016 · Open in CIViC

Researchers studied the effect of CIP2A expression in relation to gemcitabine sensitivity via SW1990 cell lines. SW1990 cells with CIP2A expression knocked-down displayed lower IC50 (p=.024), indicat… (full text at CIViC)

PMID 26894380 · Xu et al., 2016 · Open in CIViC

In a TCGA study of 295 primary gastric adenocarcinomas, fresh frozen tumors underwent several molecular techniques copy number arrays, exome sequencing, RNA sequencing, and in a subset whole genome se… (full text at CIViC)

PMID 25079317 · 2014 · Open in CIViC

In the phase 3 GLOW trial (NCT03653507), 507 patients with CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma were randomized 1:1 to receive either zolbetuximab combined with CAPOX … (full text at CIViC)

PMID 37524953 · Shah et al., 2023 · Open in CIViC

In the phase 3 SPOTLIGHT trial (NCT03504397), 565 patients with gastroesophageal junction adenocarcinoma were randomized to receive either zolbetuximab combined with mFOLFOX6 (n=283) or placebo with m… (full text at CIViC)

PMID 37068504 · Shitara et al., 2023 · Open in CIViC

CRKL amplification is observed in a subset of gastric cancers. MKN74 cells with CRKL amplification were responsive to the dual Src/BCR-ABL kinase inhibitor Dasatinib, likely via the inhibition of CRKL… (full text at CIViC)

PMID 22591714 · Natsume et al., 2012 · Open in CIViC

Frequency of point mutations in exon 3 β-catenin gene is low in our population. It would be interesting to increase the population size to test the clinically relevant influence in the prognosis found… (full text at CIViC)

PMID 25313745 · Rafael et al., 2014 · Open in CIViC

Characterization of hepatoblastoma (HB) with whole-exome sequencing identified recurrent CTNNB1 mutations in 12 of 15 tumors. All 12 impacted exon 3, including 4 missense mutations at position G34 (G3… (full text at CIViC)

PMID 25135868 · Eichenmüller et al., 2014 · Open in CIViC

The authors analyzed 52 hepatoblastoma (HB) biopsies and three HB cell lines from sporadic HBs and found 48% of them bearing mutations on beta-catenin exon 3, which encodes the degradation targeting… (full text at CIViC)

PMID 9927029 · Koch et al., 1999 · Open in CIViC

Characterization of hepatoblastoma (HB) with whole-exome sequencing identified recurrent CTNNB1 mutations in 12 of 15 tumors. All 12 impacted exon 3, including 4 missense mutations at position G34 (G3… (full text at CIViC)

PMID 25135868 · Eichenmüller et al., 2014 · Open in CIViC

Characterization of hepatoblastoma (HB) with whole-exome sequencing identified recurrent CTNNB1 mutations in 12 of 15 tumors. All 12 impacted exon 3, including 4 missense mutations at position G34 (G3… (full text at CIViC)

PMID 25135868 · Eichenmüller et al., 2014 · Open in CIViC

Characterization of hepatoblastoma (HB) with whole-exome sequencing identified recurrent CTNNB1 mutations in 12 of 15 tumors. All 12 impacted exon 3, including 4 missense mutations at position G34 (G3… (full text at CIViC)

PMID 25135868 · Eichenmüller et al., 2014 · Open in CIViC

Five mutations resulted in amino acid substitutions in codons 32 and 34, suggesting an influence on the accessibility of the serine 33 for the GSK-3β kinase, preventing its phosphorylation (Fig. 2a)

PMID 9927029 · Koch et al., 1999 · Open in CIViC

The evidence from the literature describes the association of CTNNB1 mutation to Hepatoblastoma (HB) via detecting CTNNB1 mutation in HB cell lines through molecular techniques. In conclusion, 78% (21… (full text at CIViC)

PMID 12101426 · Taniguchi et al., 2002 · Open in CIViC

Of 39 hepatoblastoma samples, 10 tumor samples had point mutations in exon 3 of beta-catenin gene. One mutation changes threonine at position 41 to alanine (T41A).

PMID 16937357 · Sugawara et al., 2007 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One of 23 pa… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

CXCR4 expression as assessed by microarray analysis, was associated with resistance to docetaxel in 11 cancer cell lines (R^2 = 0.23, p = 0.019). Expression levels (by qtPCR) were also higher in resis… (full text at CIViC)

PMID 20651371 · Xie et al., 2010 · Open in CIViC

Expression of DCC was a strong positive predictive factor for survival in both stage II and stage III colorectal carcinomas. In patients with stage II disease whose tumors expressed DCC, the five-year… (full text at CIViC)

PMID 8929264 · Shibata et al., 1996 · Open in CIViC

Expression analysis of multiple cohorts of gastric cancer patients in addition to in vivo selected metastatic cell lines, identified DDR2 as the driver of peritoneal dissemination. Within the Singapor… (full text at CIViC)

PMID 26934957 · Kurashige et al., 2016 · Open in CIViC

In HCT-116, HT-29, and SW620 colorectal cancer cells, shRNA-mediated reduction of DHFR expression significantly increased sensitivity to fluorouracil, as measured by decreased IC50. DHFR and GGH knock… (full text at CIViC)

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

Nuclear expression of DICKKOPF-1 was identified in 15% of 699 patients with colorectal cancer and was associated with decreased progression-free survival (PFS) and overall survival (OS) after chemothe… (full text at CIViC)

PMID 25788273 · Aguilera et al., 2015 · Open in CIViC

RT-PCR and FISH assays were developed for the detection of rearrangements of the PRKACA locus. A total of 106 primary liver tumors were studied by RT-PCR (26 fibrolamellar carcinomas, 25 conventional … (full text at CIViC)

PMID 25698061 · Graham et al., 2015 · Open in CIViC

A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion wa… (full text at CIViC)

PMID 24578576 · Honeyman et al., 2014 · Open in CIViC

High DNMT1 expression was found in 105/127 (83%) or patients (by qPCR assay). Low DNMT1 expression was associated with improved histopathological and clinical response and OS in patients with gastric … (full text at CIViC)

PMID 21458988 · Mutze et al., 2011 · Open in CIViC

shRNA-mediated depletion of DPYS expression significantly increased fluorouracil cytotoxicity in HCT-116, HT-29, and SW620 colorectal cancer cells, with approximately 3- to 7-fold decreases in IC50.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

shRNA-mediated DTYMK knockdown increased fluorouracil sensitivity, decreasing IC50 approximately threefold in HT-29 cells and fivefold in HCT-116 cells.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

Reduced DUT expression by shRNA increased fluorouracil sensitivity, producing approximately 13-fold and threefold reductions in IC50 in HCT-116 and SW620 cells, respectively.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high E… (full text at CIViC)

PMID 23374602 · Pentheroudakis et al., 2013 · Open in CIViC

In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial.

PMID 20840671 · Marx et al., 2010 · Open in CIViC

87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and … (full text at CIViC)

PMID 18794099 · Personeni et al., 2008 · Open in CIViC

A case report of a 49 year old female with gastric signet ring cell carcinoma, in whom a genomic screen of cf tumour DNA revealed an EGFR::SEPT14 fusion at a VAF of 45.3%. The fusion was confirmed by … (full text at CIViC)

PMID 33969073 · Kim et al., 2021 · Open in CIViC

Case report describing a 63-year-old patient with colorectal adenocarcinoma. He started treatment with XELOX and bevacizumab. After findings of disease progression, they changed to bevacizumab and FOL… (full text at CIViC)

PMID 32162810 · Li et al., 2020 · Open in CIViC

The ctDNA of 46 patients with hepatocellular carcinoma was analyzed to investigate whether EGFR alterations could lead to lenvatinib resistance. Among these patients, 16 had been treated with lenvatin… (full text at CIViC)

PMID 36708791 · Lim et al., 2023 · Open in CIViC

A total of 114 patients with gastric cancer were subject to genomic testing for amplified genes in this retrospective study. There were 4 MET amplifications, 3 EGFR amplifications, and 4 HER2 amplific… (full text at CIViC)

PMID 22042947 · Lennerz et al., 2011 · Open in CIViC

Case report describing a 63-year-old patient with colorectal adenocarcinoma with disease progression after treatment with XELOX-bevacizumab and bevacizumab-FOLFIRI. After the detection of EGFR aberrat… (full text at CIViC)

PMID 32162810 · Li et al., 2020 · Open in CIViC

Patients with refractory colorectal cancer expressing immunohistochemically detectable EGFR were randomly assigned to receive treatment with cetuximab (n=287) or receive supportive care alone (n=285).… (full text at CIViC)

PMID 18003960 · Jonker et al., 2007 · Open in CIViC